All News

joint.tap_.septic.monarthritis.jpg

Best of 2025: Distinguishing Septic and Gouty Arthritis

d Jack Cush, MD

A single center, retrospective review of patients undergoing knee joint fluid aspirations for presumed crystalline arthritis (CA) showed that synovial WBC may provide a useful diagnostic marker for SA with an optimal threshold of 50,000 cells/mm3.

Read Article
Jo1.gottrons.jpg

Best of 2025: Dermatomyositis Reviewed

d Jack Cush, MD

Researchers from the University of Pennsylvania have published an open-access review of dermatomyositis (DM) - its manifestations, hallmark cutaneous features, etiopathogenesis and treatment options.

Read Article
VitD_1.jpg

Best of 2025: Vitamin D for Prevention of Disease

d Jack Cush, MD

JAMA has published a clinical guideline on the use of vitamin D to prevent disease in children and adults.

Read Article
ILD damage fibrosis path

Best of 2025: Antifibrotics - A New Class of Therapies in Rheumatology?

d Shervin Assassi, MD

Rheumatologists typically manage systemic autoimmune rheumatic diseases and associated interstitial lung disease with immunosuppressants. However, evidence increasingly supports also the use of antifibrotic agents in this setting.

Read Article
MTX.pills

Best of 2025: Methotrexate intolerance in rheumatoid arthritis

d Jack Cush, MD

Methotrexate (MTX) is the most commonly used DMARD in rheumatoid arthritis (RA); however, there is significant intolerance to this drug among adult RA patients - especially at doses above 15 mg per week.

Read Article
Vexas

Best of 2025: Overview of the VEXAS Syndrome

d Jack Cush, MD

A current systematic review in Rheumatology addresses the clinical features seen in the VEXAS syndrome.

Read Article
FDA,approved,stamp,blue

Nerandomilast FDA Approved for Progressive Pulmonary Fibrosis

d Jack Cush, MD

The FDA has approved nerandomilast (Jascayd), a PDE4b inhibitor, to treat adults with progressive pulmonary fibrosis (PPF). Nerandomilast was approved to treat idiopathic pulmonary fibrosis (IFP) in October 2025.  

Read Article
APP Pearls “Never stop learning—rheumatology is full of surprises” - Kayla Carlucci, FNP-BC

Dr. John Cush RheumNow ( View Tweet)

Nerandomilast FDA Approved for Progressive Pulmonary Fibrosis The FDA has approved nerandomilast (Jascayd), a PDE4b inhibitor, to treat adults with progressive pulmonary fibrosis (PPF). Nerandomilast was approved to treat idiopathic pulmonary fibrosis (IFP) in October 2025. https://t.co/G2SS0qJTfl
Dr. John Cush RheumNow ( View Tweet)
Three Things to Know About Hiring, Onboarding, and Training APPs As the utilization of APPs (nurse practitioners and physician assistants) in rheumatology becomes more prevalent, here are three things to consider if you are thinking about adding an APP to your practice: Read https://t.co/24RVd09vcK
Dr. John Cush RheumNow ( View Tweet)
Telling You Where to Go (12.19.2025) Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow. Who would've thunk - a PsA FMF connection? Labs to diagnose SSc-ILD? IgA-RF may be important or RZV may not work in JAK inhibitor treated patients? https://t.co/bwF89L9Z7R
Dr. John Cush RheumNow ( View Tweet)
APP Controversies and Misconceptions In this Tuesday Night Rheumatology, panelists discuss a range of topics, including APP roles and impact; models of care; independence; seeing new patients and complex cases; and more. Panelists: Daric A. Mueller, PA-C; Lisa Carnago, PhD, https://t.co/t2PssfUNoV
Dr. John Cush RheumNow ( View Tweet)
APP Pearls “You must assess sleep and mood- without this, even if you control all inflammation, you will not control pain and fatigue!” - Christine Stamatos, NP, DNP, RN

Dr. John Cush RheumNow ( View Tweet)

Tricks of the Trade – Clinic Advice from APPs December 2025 is focused on advanced practice providers, their impact, education and priorities. In seeking and soliciting the help and advice of leaders in the rheumatology APP world, I have been impressed by APP pride, dedication https://t.co/boyjytkUyq
Dr. John Cush RheumNow ( View Tweet)
Hidden in Plain Sight: IBD As a PA with six years of experience in rheumatology and a background in gastroenterology, today I'm discussing the clinical overlap between inflammatory arthritis—particularly psoriatic arthritis and spondyloarthropathies—and inflammatory bowel https://t.co/Aatc4jkbpH
Dr. John Cush RheumNow ( View Tweet)
Disease Activity Criteria for Adult-Onset Still's Disease: EULAR Points to Consider EULAR has published a "points to consider" (PtCs) guidance on the development of criteria for the assessment of the disease activity in adult-onset Still’s disease (AOSD). https://t.co/3FikFiGgxM
Dr. John Cush RheumNow ( View Tweet)
NPs and PAs: Opportunities Outside of the Exam Room Ben Smith, PA-C, Thomasville, GA, discusses scholarly and leadership opportunities for nurse practitioners and physician assistants, as part of RheumNow's "Mission: APP Partners in Care" campaign during the month of December. https://t.co/Vzx6B1z2xJ
Dr. John Cush RheumNow ( View Tweet)
Lancet review of skin cancer risk w/ inflammatory arthritis - both melanoma and Non-melanoma skin cancers are increased in RA & inflammation. Also Package inserts for TNFi say all TNFi Rx pts should have complete skin exams "periodically". Skin cancer screening advised. https://t.co/XddFDe0xh8
Dr. John Cush RheumNow ( View Tweet)
“Absence of proof of efficacy does not equal proof of absence of efficacy” - Arthur Kavanaugh, MD

Dr. John Cush RheumNow ( View Tweet)

Japanese retrospective study-194 #RA pts Rx w/ JAK inhib (74 vaccinated w/ recombinant zoster (RZV) & 120 Not-Vax). H.zoster lower w/ RZV (4.8/100PY) vs UnVax (7.8/100PY) w/ overall efficacy of 59.1%. RSV Vax pts who got HZ had signif lower lymphocyte #s, higher SDAI & CDAI. https://t.co/vJJRflJ23x
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×